ClinicalTrials.gg
TerminatedNCT01144741STOP-FSSUpdated Jun 21, 2022

Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome

An observational study in Freeman-Sheldon Syndrome, Arthrogryposis Distal Type 2A and Whistling Face Syndrome, sponsored by Freeman-Sheldon Research Group, Inc.. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2022-06-21.

Sponsored by Freeman-Sheldon Research Group, Inc. · Observational

Why this study was terminated
Insufficient patient enrolment
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
2
Sex
All
01

Study summary

Freeman-Sheldon syndrome (FSS) is a rare muscle disorder present before birth, involving primarily problems of the face and skull and the hands and feet.

This is a study of problems, experiences, helpful treatments, and quality of life focusing on patients with FSS but including patients with Sheldon-Hall syndrome (SHS), distal arthrogryposis type 1 (DA1), and distal arthrogryposis type 3 (DA3), also called Gorden syndrome. These and related disorders are very challenging to treat, partly because the big differences in individual patients and lack of information on previous clinical experience with treatment options. It is hoped the study will identify areas for further research in physiology and therapy.

This study will cover all types of treatment [medical (non-surgical), including psychiatric, and surgical treatments], even unconventional. It also includes questions about effects on the patient's thoughts, feelings, quality of life, and relationship with siblings, family, and parents' and if any intervention was required or advised. This study will also look for similarities and differences in patients who meet the head and face part of the diagnostic criteria but do not meet all other parts and patients who met the full diagnostic criteria. There will be questions about problems or experiences to investigate if both groups of patients may have the same syndrome. Treatment success depends on getting a correct diagnosis.

Read the detailed description

This study was initiated by the research assistant (Mikaela I. Poling) and assisted by another research assistant (J. Andrés Morales), as part of their academic project on these syndromes, under the supervision of the Principal Investigator (Robert L Chamberlain).

Classic FSS, SHS, DA1, and DA3 are poorly understood pathological entities that share some similar physical findings to FSS. Stevenson et al. (2006) provided the only study to date on FSS features and history. They did not, however, focus on therapeutic outcomes, and there was limited anecdotal outcome data in single and multiple case reports.

The objectives for STOP-FSS are as follows: to evaluate (1) physical findings, possible frequency clusters, and complications of physical findings amongst patients with FSS; (2) posttraumatic stress and depressive symptoms and associated therapeutic outcomes in patients with FSS, using single-disease specific (i.e., posttraumatic stress symptoms, chronic depression) measures; (3) document treatment types and outcomes; (4) evaluate quality of life in patients with FSS, using a general quality of life self-report measure and syndrome-specific semi-structured quality of life interview; (5) educational attainment and services used; (6) evaluate diagnostic accuracy of FSS and SHS, using the Stevenson criteria; and (7) evaluate possible differences with patients meeting the full Stevenson criteria and those fulfilling the craniofacial part of the Stevenson criteria, with or without additional malformations.

The following hypotheses are thus proposed. First, it is suggested that physical findings and frequency clusters will be similar to those previously reported, but complications of physical findings amongst patients with FSS, having received little attention in the literature, will be pronounced and result in nearly as significant of a disease burden for the patient as the primary physical findings themselves, e.g., intercostal myopathy eventually leading to right heart failure in some patients. Second, it is suggested that FSS is associated with higher rates of posttraumatic stress symptoms, depressive symptoms than is observed in the general population. Third, it is suggested that physiotherapy alone or with surgery is expected to be superior to surgery alone, especially for patients with FSS, in treating most problems, but surgery may have an important role, especially treating blepharophimosis and in combination with intensive pre- and post-operative physiotherapy in treating selective tendon lengthening in hands and feet. Fourth, it is suggested that FSS is associated with reduced quality of life than is observed in the general population. Fifth, it is suggested that when patients with FSS who do not have neurocognitive features receive the appropriate academic services, they frequently excel beyond family and peers, and it is also suggested that most patients with FSS do not receive educational services that are responsive to their unique needs and abilities, e.g., placement in 'special' classes or schools based on the patient's appearance or poorly conducted intelligence tests. Sixth, it is suggested, based on systematic review and meta-analysis preliminary results, that two-thirds of patients with a stated diagnosis of FSS will not meet the Stevenson criteria and be rediagnosed, mostly as DA1. Seventh, it is suggested, based on systematic review and meta-analysis preliminary results, that two-thirds of patients with stated diagnosis of FSS who do not meet the Stevenson criteria, one-third will be meet the craniofacial stipulates of the Stevenson criteria, with or without additional malformations, and share a natural history with those who met the full Stevenson criteria.

02

Conditions studied

  • Freeman-Sheldon Syndrome
  • Arthrogryposis Distal Type 2A
  • Whistling Face Syndrome
  • Craniocarpotarsal Dysplasia
  • Craniocarpotarsal Dystrophy
  • Freeman-Sheldon Syndrome Variant
  • Sheldon-Hall Syndrome
  • Arthrogryposis Distal Type 2B
  • Gordon Syndrome
  • Arthrogryposis Distal Type 3
  • Arthrogryposis Distal Type 1
  • Arthrogryposis, Distal, Type 1A
  • Arthrogryposis Distal Type 1B
  • Arthrogryposis, Distal
  • Craniofacial Abnormalities
  • Arthrogryposis

Keywords

  • rehabilitation
  • surgery
  • therapy
  • Quality Of Life
  • Health-Related Quality Of Life
  • Health Status
  • Depressive Symptoms
  • Situational Depression
03

In context

Arthrogryposis

16 studies on the registry are indexed under Arthrogryposis; 5 are open to participants now.

Browse Arthrogryposis studies →

Lead sponsor

Freeman-Sheldon Research Group, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

There are no patient enrollment restrictions based on gender, ethnicity, religion, socio-economic status, geographical location, or clinical setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have phenotypes consistent with (1) the Stevenson criteria for classic FBS or SHS; (2) one of four tentative FBS subtypes; or (3) DA1A, DA1B, or DA3.
  • Any of the following: (1) patients or parents of minor children willing to give consent, or (2) patients who are deceased or (3) retrospective chart review patients (living or deceased) who have enough clinical data available to establish the diagnosis and satisfy minimum data collection requirements.
  • Persons who speak English, Spanish, German, Russian, or Czech.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not have phenotypes consistent with (1) the Stevenson criteria for classic FBS or SHS; (2) one of four tentative FBS subtypes; or (3) DA1A, DA1B, or DA3.
  • Any of the following: (1) patients or parents of minor children not willing to give consent, or (2) patients who are deceased or (3) retrospective chart review patients (living or deceased) who do not have enough clinical data available to establish the diagnosis and satisfy minimum data collection requirements.
  • Potentially persons who speak languages other than English, Spanish, German, Russian, or Czech, subject to translator availability
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
2 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Freeman-Sheldon syndrome Classic Type

    Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); "H" or "V" shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.

    Other: PTSD Checklist-Civilian (PCL-C) · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale (CES-D) · Other: Functional Enquiry (or Review of Systems) Form · Other: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire · Other: FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI) · Other: Medical Records Review

  • Freeman-Sheldon syndrome Craniofacial Type

    Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), "H" or "V" shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases).

    Other: PTSD Checklist-Civilian (PCL-C) · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale (CES-D) · Other: Functional Enquiry (or Review of Systems) Form · Other: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire · Other: FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI) · Other: Medical Records Review

  • Freeman-Sheldon syndrome Mixed Type

    Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.

    Other: PTSD Checklist-Civilian (PCL-C) · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale (CES-D) · Other: Functional Enquiry (or Review of Systems) Form · Other: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire · Other: FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI) · Other: Medical Records Review

  • Sheldon-Hall syndrome

    Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.

    Other: PTSD Checklist-Civilian (PCL-C) · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale (CES-D) · Other: Functional Enquiry (or Review of Systems) Form · Other: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire · Other: FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI) · Other: Medical Records Review

  • Distal Arthrogryposis Type 1

    Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.

    Other: PTSD Checklist-Civilian (PCL-C) · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale (CES-D) · Other: Functional Enquiry (or Review of Systems) Form · Other: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire · Other: FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI) · Other: Medical Records Review

  • Distal Arthrogryposis Type 3

    Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and backbones curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.

    Other: PTSD Checklist-Civilian (PCL-C) · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale (CES-D) · Other: Functional Enquiry (or Review of Systems) Form · Other: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire · Other: FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI) · Other: Medical Records Review

Interventions

  • OtherPTSD Checklist-Civilian (PCL-C)

    Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.

  • OtherModified Flanagan Quality of Life Scale

    Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.

    Also known as: Quality of Life Scale, Quality of Life Instrument, Quality of Life Measure

  • OtherCenter for Epidemiologic Studies Depression Scale (CES-D)

    Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.

  • OtherFunctional Enquiry (or Review of Systems) Form

    Completed during the interview; it is a checklist of medical problems.

    Also known as: Health History, Systems Review, Medical History

  • OtherStudy of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire

    The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.

  • OtherFSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)

    Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.

    Also known as: Quality of Life Assessment, quality of life instrument, quality of life measure

  • OtherMedical Records Review

    Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.

    Also known as: Treatment Records Review, Review of Patient Notes, Patient Chart Review, Review of Clinical Data

06

What researchers measure

Primary outcomes

  1. Physical Findings and Complications of Physical Findings

    The frequency to which certain features of the syndromes contribute to mortality or morbidity, especially life-long functional impairment.

    Time frame: during a single study interview, which lasts 1-2 hours

Secondary outcomes

  1. Posttraumatic Stress and Depressive Symptoms

    Increased frequency of mental health symptoms (posttraumatic and depressive) over expected for general population

    Time frame: at study enrolment and during a single study interview, which lasts 1-2 hours

Other outcomes

  1. Intervention-Related Outcome

    Self-report or medical record evidence of ability to complete activities of daily living and instrumental activities of daily living compared with abilities before each intervention reported and, if relevant, how long this change in abilities lasted

    Time frame: during a single study interview, which lasts 1-2 hours

  2. Quality of Life Status

    Stated and evidenced experience of life

    Time frame: at enrolment and during a single study interview, which lasts 1-2 hours

  3. Educational attainment

    Educational level completed compared with age

    Time frame: during a single study interview, which lasts 1-2 hours

  4. Diagnostic Accuracy for Freeman-Sheldon and Sheldon-Hall syndromes

    Correct diagnosis, using the Stevenson criteria

    Time frame: at study enrolment

  5. Correlations of Full and Partial Stevenson Criteria Freeman-Sheldon syndrome with

    Significant differences or correlations of patients meeting the full Stevenson criteria for FSS with those fulfilling the craniofacial part of the Stevenson criteria, with or without additional malformations

    Time frame: at study enrolment and during a single study interview, which lasts 1-2 hours

07

Study locations

1 site
  • Freeman-Sheldon Research Group, Inc. Headquarters
    Buckhannon, West Virginia 26201, United States
08

References and documents

Publications

  • Poling MI, Morales Corado JA, Chamberlain RL. Findings, phenotypes, and outcomes in Freeman-Sheldon and Sheldon-Hall syndromes and distal arthrogryposis types 1 and 3: protocol for systematic review and patient-level data meta-analysis. Syst Rev. 2017 Mar 6;6(1):46. doi: 10.1186/s13643-017-0444-4. PubMed 28264711 ↗
  • Chamberlain RL, Poling MI, Portillo AL, Morales A, Ramirez RR, McCormick RJ. Freeman-Sheldon syndrome in a 29-year-old woman presenting with rare and previously undescribed features. BMJ Case Rep. 2015 Oct 22;2015:bcr2015212607. doi: 10.1136/bcr-2015-212607. PubMed 26494722 ↗

Individual participant data

Plan to share: No — Individual patient data will not be shared, due to concerns involved in masking identities of individuals with such a rare condition.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2010 to primary completion in Jun 2022, 148 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2010
First posted
Jun 16, 2010
StartActual
Feb 2010
Primary completionActual
Jun 14, 2022
CompletionActual
Jun 14, 2022
Last update
Jun 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01144741
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Responsible party
Sponsor
First posted
Jun 16, 2010
Start date
Feb 2010
Primary completion
Jun 14, 2022
Completion
Jun 14, 2022
Last update
Jun 21, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion